News Release

DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 24, 2018 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 12, 2018 and are available on the ICON plc website.

The final results of the voting are as follows:

RESOLUTION NUMBER		RESOLUTION		TOTAL NUMBER OF VOTES		VOTE FOR		VOTE AGAINST		VOTE WITHHELD
1.1		To re-elect Mr. Ciaran Murray		46,363,577		43,309,546		3,049,154		4,877
1.2		To re-elect Mr. Declan McKeon		46,363,577		45,438,950		919,871		4,756
1.3		To re-elect Mr. Eugene McCague		46,363,577		46,158,700		200,090		4,787
1.4		To re-elect Ms. Joan Garahy		46,363,577		46,160,214		198,360		5,003
2		To review the Company's affairs and consider the accounts and reports		46,363,577		46,233,943		1,906		127,728
3		To authorise the fixing of the auditors' remuneration		46,363,577		43,981,210		2,377,642		4,725
4		To authorise the Company to allot shares		46,363,577		45,518,647		831,568		13,362
5**		To disapply pre-emption rights		46,363,577		46,218,055		126,968		18,554
6**		To disapply pre-emption rights for funding capital investment or acquisitions		46,363,577		46,159,710		186,608		17,259
7**		To authorise the Company to make market purchases of shares		46,363,577		45,717,396		461,062		185,119
8**		To authorise the price range at which the Company can reissue shares it holds as treasury shares		46,363,577		46,253,806		97,134		12,637

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. Further information is available at www.iconplc.com.

Source: ICON plc

All at ICON.

ICON/ICLR-F

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20180725005262/en/

ICON plc
Investor Relations
1 888 381 7923
or
Brendan Brennan
Chief Financial Officer
+ 353 1 291 2000
Jonathan Curtain
Vice President Corporate Finance and Investor Relations
+1 215 616 3000

Source: ICON plc

 

 

News Provided by Acquire Media